You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Previously treated MDS

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

MDS, Secondary Acute Myeloid Leukemia (AML) Trial in United States (Clofarabine)

Completed
Has Results
  • Myelodysplastic Syndromes
  • Secondary Acute Myeloid Leukemia (AML)
  • Chicago, Illinois
  • +5 more
Mar 15, 2022

Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Refractory High Risk Myelodysplastic Syndrome Trial in

Completed
  • Myelodysplastic Syndrome
  • +4 more
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Oct 11, 2021

MDS Over Time - Comparison of Treated vs Untreated Patients

Completed
  • Myelodysplastic Syndromes
    • Vienna, Austria
      Hanusch Krankenhaus, 3.Medizinische Abteilung
    Nov 21, 2022

    Acute Myeloid Leukemia, Myelodysplastic Syndrome, Uveal Melanoma Trial in Denver, Portland, Nashville (BPX-701, Rimiducid)

    Unknown status
    • Acute Myeloid Leukemia
    • +2 more
    • Denver, Colorado
    • +2 more
    Apr 23, 2020

    Solid Tumor, Adult Trial in Shanghai (Tislelizumab, Lenvatinib, Cryoablation)

    Recruiting
    • Solid Tumor, Adult
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Sep 13, 2023

    High Grade MDS Trial in Aurora (Omacetaxine, Azacitidine)

    Recruiting
    • High Grade Myelodysplastic Syndromes
    • Aurora, Colorado
      Universtiy of Colorado Denver
    Nov 17, 2022

    Peri-implant Mucositis, Peri-Implantitis Trial in Pittsburgh (Induction of experimental peri-implant mucositis, Resolution of

    Recruiting
    • Peri-implant Mucositis
    • Peri-Implantitis
    • Induction of experimental peri-implant mucositis
    • Resolution of experimental peri-implant mucositis
    • Pittsburgh, Pennsylvania
      University of Pittsburgh School of Dental Medicine
    Sep 25, 2023

    Pancreatic Ductal Adenocarcinoma, Pancreas Adenocarcinoma, Pancreas Cancer Trial in Kansas City (Enfortumab vedotin)

    Recruiting
    • Pancreatic Ductal Adenocarcinoma
    • +2 more
    • Enfortumab vedotin
    • Kansas City, Kansas
      University of Kansas Cancer Center
    Jun 23, 2023

    Colorectal Cancer Trial (ME-344, Bevacizumab)

    Not yet recruiting
    • Colorectal Cancer
    • (no location specified)
    Apr 20, 2023

    Solid Tumor Trial (IN10018, Nab-paclitaxel, Tislelizumab)

    Not yet recruiting
    • Solid Tumor
    • (no location specified)
    Aug 1, 2023

    Soft Tissue Sarcoma Trial (ADI PEG20, Placebo)

    Not yet recruiting
    • Soft Tissue Sarcoma
    • ADI PEG20
    • Placebo
    • (no location specified)
    Jan 31, 2023

    Colorectal Cancer Trial (Tislelizumab, Irinotecan Hydrochloride, cetuximab)

    Not yet recruiting
    • Colorectal Cancer
    • (no location specified)
    Mar 23, 2023

    Long Term Efficacy and Safety Trial (Imlifidase administered in the 20-HMedIdeS-19 (PAES) study, Best available treatment

    Not yet recruiting
    • Long Term Efficacy and Safety
    • Imlifidase administered in the 20-HMedIdeS-19 (PAES) study
    • Best available treatment administered in the 20-HMedIdeS-19 (PAES) study
    • (no location specified)
    Jun 30, 2023

    Primary Immune Thrombocytopenia (ITP) Trial (Ianalumab)

    Not yet recruiting
    • Primary Immune Thrombocytopenia (ITP)
    • Ianalumab
    • (no location specified)
    Jun 5, 2023

    Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1

    Not yet recruiting
    • Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
    • Ivosidenib 500mg
    • Placebo
    • (no location specified)
    Nov 7, 2023

    Advanced Biliary Tract Cancer Trial in Shanghai (Sintilimab, Lenvatinib, Cryoablation)

    Recruiting
    • Advanced Biliary Tract Cancer
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Mar 22, 2023

    Participants Previously Treated With Century Therapeutics

    Not yet recruiting
    • Hematological Malignancy
    • Solid Tumor Malignancy
    • No Intervention
    • (no location specified)
    Mar 3, 2023

    NSCLC, NSCLC Trial in Guangzhou (Apatinib + Fluzoparib, Apatinib + Fluzoparib + Adebrelimab)

    Not yet recruiting
    • NSCLC
    • Non-small Cell Lung Cancer
    • Apatinib + Fluzoparib
    • Apatinib + Fluzoparib + Adebrelimab
    • Guangzhou, Guangdong, China
      Sun Yat-Sen University Cancer Center
    Jun 27, 2023

    Participants Previously Treated With EB-101 for Treatment of

    Enrolling by invitation
    • RDEB
    • EB-101
    • Redwood City, California
    • +1 more
    Feb 1, 2023

    Colorectal Cancer Metastatic Trial (EO2401)

    Not yet recruiting
    • Colorectal Cancer Metastatic
    • (no location specified)
    Feb 2, 2023

    Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic Trial (Ivosidenib)

    Not yet recruiting
    • Cholangiocarcinoma Non-resectable
    • Cholangiocarcinoma Metastatic
    • (no location specified)
    Oct 10, 2023

    Diabetic Kidney Disease, CAKUT, Chronic Kidney Diseases Trial (Renal Autologous Cell Therapy (REACT))

    Not yet recruiting
    • Diabetic Kidney Disease
    • +2 more
    • Renal Autologous Cell Therapy (REACT)
    • (no location specified)
    Jan 11, 2023

    Nasopharyngeal Carcinoma Trial in Beijing (Donafenib)

    Recruiting
    • Nasopharyngeal Carcinoma
    • Beijing, Beijing, China
      Cancer Hospital of Medical College
    Nov 28, 2022

    Kaposi Sarcoma, Classic Kaposi Sarcoma, Refractory Kaposi Sarcoma Trial (Pembrolizumab + Lenvatinib)

    Not yet recruiting
    • Kaposi Sarcoma
    • +2 more
    • Pembrolizumab + Lenvatinib
    • (no location specified)
    Apr 27, 2023

    NSCLC Trial (SGN-B6A, docetaxel)

    Not yet recruiting
    • Carcinoma, Non-Small-Cell Lung
    • (no location specified)
    Aug 21, 2023